Patent details
LUC00332 Product Name: Gefapixant, ou un sel pharmaceutiquement acceptable de celui-ci
Basic Information
- Publication number:
- LUC00332
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP168523405
- Legal Status:
- Inactive
- Application number:
- LUC00332
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/21/1613
- Marketing Authorization Type:
- Marketing Authorization Date:
- 20/09/2023
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 14/03/2024
- First Marketing Authorization date:
- 20/09/2023
- Grant date:
- 04/03/2026
- Activation date:
- Publication date:
- 14/03/2024
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 20/09/2038
- SPC Extension Expiration:
- 20/09/2038
- Rejection date:
- Withdrawal date:
Owner
- From:
- 14/03/2024
- Name:
- Afferent Pharmaceuticals Inc.
- Address:
- 126 East Lincoln Avenue Rahway, New Jersey 07065, United States (US)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 14/03/2024
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Publication
Bulletin
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2024/05
- Publication date:
- 03/04/2024
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
Annual Fees
- Annual Fee Due Date:
- 30/09/2036
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|---|---|
| 14/03/2024 | Marketing authorization | 3 |
| 14/03/2024 | Application Form | 3 |
| 14/03/2024 | Summary of the product caracteristics | 31 |
| 14/03/2024 | MA publication | 3 |
| 14/03/2024 | Outgoing Correspondence | 1 |
| 14/03/2024 | Publication | 1 |
| 04/03/2026 | Publication | 1 |
| 04/03/2026 | Certificate | 1 |
| 04/03/2026 | Outgoing Correspondence | 1 |